Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-Derived Stromal Cells for Pressure Ulcers or Diabetic Foot Ulcers
NCT02375802Phase 1Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Jul 2015
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adipose derived mesenchymal stromal cells in pressure ulcer and diabetic foot ulcer (DFU), sponsored by Mayo Clinic. Primary endpoint: Free of wound infection at 1 week. Started Jul 2015; status: enrolling by invitation.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
pressure ulcerdiabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02375802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375802.